PRPO - Precipio, Inc. Annual Revenue Growth (Last Twelve Months)

The year-over-year sales trend over the last 12 months demonstrates the results of Precipio, Inc. (PRPO), which combines the production of laboratory reagents with oncology diagnostics to mitigate insurance risks. The current status is 21.50, which is a critical factor when analyzing the operational logistics of biomaterial collection. However, aggressive test marketing currently outweighs revenues, creating a liquidity deficit and negative cash flow.
Precipio Inc (PRPO) - metric breakdowns and financial figures

Year-over-year (TTM) sales growth measures the percentage change in revenue over the last twelve months, neutralizing seasonality. Investors use this indicator to assess business scalability and demand resilience. By analyzing the annual growth in sales volumes over a rolling four-quarter period, one can evaluate the commercial implementation efficiency of Precipio, Inc. (PRPO) HulaNexus and ICE-Cold PCR platforms. This trend captures the pace of expansion into US oncology centers. Growth confirms the demand for specialized reagents.